- TWD3.81bn
 - TWD6.48bn
 - TWD1.93bn
 
- 18
 - 25
 - 95
 - 42
 
Annual balance sheet for Bionime, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st  | 2021 December 31st  | 2022 December 31st  | 2023 December 31st  | 2024 December 31st  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | 
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 343 | 313 | 278 | 449 | 383 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 469 | 379 | 700 | 528 | 723 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,457 | 1,390 | 1,637 | 1,617 | 1,774 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,698 | 2,693 | 2,701 | 2,849 | 2,874 | 
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 4,485 | 4,564 | 4,983 | 5,301 | 5,781 | 
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,241 | 1,329 | 1,411 | 1,609 | 2,311 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 2,419 | 2,495 | 2,911 | 3,315 | 3,901 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 2,066 | 2,069 | 2,072 | 1,986 | 1,880 | 
| Total Liabilities & Shareholders' Equity | 4,485 | 4,564 | 4,983 | 5,301 | 5,781 | 
| Total Common Shares Outstanding |